share_log

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Cybin | 6-K:外國發行人報告
SEC announcement ·  04/10 17:28
Moomoo AI 已提取核心訊息
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
Cybin Inc., a clinical-stage biopharmaceutical company, has announced that its CEO, Doug Drysdale, will present at the Bloom Burton & Co. Healthcare Investor Conference on April 16, 2024. The conference will be held in Toronto, Ontario, and Drysdale's presentation is scheduled to be webcast live at 1:30 p.m. ET. Cybin, known for developing innovative psychedelic treatment options for mental health conditions, is currently working on CYB003, a treatment for major depressive disorder, and CYB004 for generalized anxiety disorder. The company, which was founded in 2019, operates in multiple countries and continues to focus on advancing its proprietary drug discovery platforms and treatment regimens.
臨床階段的生物製藥公司Cybin Inc. 宣佈,其首席執行官道格·德賴斯代爾將出席布魯姆·伯頓公司。2024年4月16日的醫療保健投資者大會。會議將在安大略省多倫多舉行,德賴斯代爾的演講定於美國東部時間下午 1:30 進行網絡直播。Cybin 以開發針對心理健康狀況的創新迷幻治療方案而聞名,目前正在研究 CYB003(一種治療重度抑鬱症的藥物)和治療廣泛性焦慮症的 CYB004。該公司成立於2019年,在多個國家開展業務,並將繼續專注於推進其專有藥物發現平台和治療方案。
臨床階段的生物製藥公司Cybin Inc. 宣佈,其首席執行官道格·德賴斯代爾將出席布魯姆·伯頓公司。2024年4月16日的醫療保健投資者大會。會議將在安大略省多倫多舉行,德賴斯代爾的演講定於美國東部時間下午 1:30 進行網絡直播。Cybin 以開發針對心理健康狀況的創新迷幻治療方案而聞名,目前正在研究 CYB003(一種治療重度抑鬱症的藥物)和治療廣泛性焦慮症的 CYB004。該公司成立於2019年,在多個國家開展業務,並將繼續專注於推進其專有藥物發現平台和治療方案。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息